SMR 2024 | MERLIN_001: predicting SN status with gene expression profile testing in melanoma

Vernon Sondak • 14 Oct 2024

SMR 2024

Melanoma Skin Cancer

MERLIN_001

Vernon Sondak, MD, Moffitt Cancer Center, Tampa, FL, discusses findings from the MERLIN_001 trial (NCT04759781), which evaluated the role of gene expression profile testing in assessing risk of lymph node metastasis in localized melanoma. The test analyzed tumor gene expression to predict the likelihood of sentinel node (SN) involvement and the test effectively stratified patients into high- and low-risk categories for metastasis, guiding sentinel node biopsy decisions. The potential cost savings and clinical benefits of this testing approach were also explored. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.